Literature DB >> 14734137

N-acetylcysteine inhibits interleukin-17-induced interleukin-8 production from human airway smooth muscle cells: a possible role for anti-oxidative treatment in chronic lung rejection?

Wim A Wuyts1, Bart M Vanaudenaerde, Lieven J Dupont, Dirk E Van Raemdonck, Maurits G Demedts, Geert M Verleden.   

Abstract

BACKGROUND: Long-term survival of lung transplantation is threatened by obliterative bronchiolitis, or its clinical equivalent, bronchiolitis obliterans syndrome. With a prevalence of >50% at 5 years after transplantation, it has emerged as the most significant long-term complication. Neutrophilic inflammation and increased interleukin (IL)-8 production seem to be part of the basic pathophysiologic mechanism of chronic rejection. Recently, it has been suggested that reactive oxygen species may also play an important role in the pathogenesis because they are known to induce smooth muscle proliferation.
METHODS: Human airway smooth muscle cells in vitro were stimulated with IL-17 (0.1 to 10 ng/ml) or with IL-17 (10 ng/ml) and the anti-oxidative agent N-acetylcysteine (1 micromol/liter to 10 mmol/liter). Production of 8-isoprostane was measured with a commercially available enzyme immunoassay kit and production of IL-8 was measured using a standard enzyme-linked immunoassay technique.
RESULTS: IL-17 produced a concentration-dependent increase in 8-isoprostane with a maximum of 136.5 +/- 15.5 pg/ml with IL-17 (10 ng/ml, p < 0.001, n = 12, vs unstimulated cells). N-acetylcysteine (NAC) was able to decrease IL-17-induced 8-isoprostane production, with a maximum decrease of 59.3 +/- 9% (p < 0.001, n = 12) with 10 mmol/liter of N-acetylcysteine, which also decreased IL-17-induced IL-8 production in a concentration-dependent manner (with maximum inhibition of 86.3% when combined with NAC 10 mmol/liter as compared with IL-17 alone).
CONCLUSIONS: We demonstrated that human airway smooth muscle cells, when stimulated with IL-17, are able to produce 8-isoprostane, which could be inhibited by adding N-acetylcysteline, and which was also able to decrease IL-17-induced IL-8 production. The clinical significance of these in vitro findings for prevention or treatment of chronic rejection after lung transplantation remains to be investigated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734137     DOI: 10.1016/s1053-2498(03)00099-8

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  7 in total

1.  N-acetylcysteine is effective for prevention but not for treatment of folic acid-induced acute kidney injury in mice.

Authors:  Hong-Zhi Wang; Zhi-Yong Peng; Xiao-Yan Wen; Thomas Rimmelé; Jeffery V Bishop; John A Kellum
Journal:  Crit Care Med       Date:  2011-11       Impact factor: 7.598

2.  Transforming growth factor-β and nuclear factor E2–related factor 2 regulate antioxidant responses in airway smooth muscle cells: role in asthma.

Authors:  Charalambos Michaeloudes; Po-Jui Chang; Mario Petrou; Kian Fan Chung
Journal:  Am J Respir Crit Care Med       Date:  2011-10-15       Impact factor: 21.405

3.  Amiodarone with or without N-Acetylcysteine for the Prevention of Atrial Fibrillation after Thoracic Surgery: A Double-blind, Randomized Trial.

Authors:  David Amar; Hao Zhang; Mina K Chung; Kay See Tan; Dawn Desiderio; Bernard J Park; Alessia Pedoto; Nancy Roistacher; James M Isbell; Daniela Molena; Ginger L Milne; Bryan F Meyers; Gregory W Fischer; Valerie W Rusch; David R Jones
Journal:  Anesthesiology       Date:  2022-06-01       Impact factor: 7.892

4.  Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival.

Authors:  R Todd Stravitz; Arun J Sanyal; Joan Reisch; Jasmohan S Bajaj; Farid Mirshahi; Jenfeng Cheng; William M Lee
Journal:  Liver Int       Date:  2013-06-19       Impact factor: 5.828

5.  TGF-β regulates Nox4, MnSOD and catalase expression, and IL-6 release in airway smooth muscle cells.

Authors:  Charalambos Michaeloudes; Maria B Sukkar; Nadia M Khorasani; Pankaj K Bhavsar; Kian Fan Chung
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-03       Impact factor: 5.464

6.  Follow-up on the therapeutic effects of a budesonide, azithromycin, montelukast, and acetylcysteine (BAMA) regimen in children with post-infectious bronchiolitis obliterans.

Authors:  Tingting Weng; Xixi Lin; Leying Wang; Jiamei Lv; Lin Dong
Journal:  J Thorac Dis       Date:  2021-08       Impact factor: 2.895

7.  Therapeutic effect of budesonide/formoterol, montelukast and N-acetylcysteine for bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.

Authors:  Sei Won Kim; Chin Kook Rhee; Yoo Jin Kim; Seok Lee; Hee Je Kim; Jong Wook Lee
Journal:  Respir Res       Date:  2016-05-26
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.